CARGO Therapeutics, Inc. (CRGX)

NASDAQ: CRGX · Real-Time Price · USD
3.590
+0.110 (3.16%)
Feb 12, 2025, 4:00 PM EST - Market closed
3.16%
Market Cap 165.24M
Revenue (ttm) n/a
Net Income (ttm) -154.14M
Shares Out 46.03M
EPS (ttm) -4.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 375,528
Open 3.400
Previous Close 3.480
Day's Range 3.400 - 3.600
52-Week Range 3.000 - 33.920
Beta n/a
Analysts Hold
Price Target 4.67 (+30.08%)
Earnings Date Mar 20, 2025

About CRGX

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company’s lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, In... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 10, 2023
Employees 116
Stock Exchange NASDAQ
Ticker Symbol CRGX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for CRGX stock is "Hold." The 12-month stock price forecast is $4.67, which is an increase of 30.08% from the latest price.

Price Target
$4.67
(30.08% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Bronstein, Gewirtz & Grossman, LLC Encourages CARGO Therapeutics, Inc. (CRGX) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company")...

19 hours ago - Accesswire

The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation

LOS ANGELES, CA / ACCESS Newswire / February 11, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Th...

1 day ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating CARGO Therapeutics, Inc. (CRGX) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company")...

1 day ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CARGO Therapeutics, Inc. (CRGX) And Encourages Shareholders to Reach Out

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company")...

2 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages CARGO Therapeutics, Inc. (CRGX) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

3 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CARGO Therapeutics, Inc. (CRGX) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

5 days ago - Accesswire

CRGX Investors Have Opportunity to Join CARGO Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

LOS ANGELES , Feb. 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, I...

6 days ago - PRNewsWire

CARGO Therapeutics, Inc. (CRGX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

6 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating CARGO Therapeutics, Inc. (CRGX) And Encourages Investors to Connect

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

7 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CARGO Therapeutics, Inc. (CRGX) and Encourages Stockholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

8 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages CARGO Therapeutics, Inc. (CRGX) Investors to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / February 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

9 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CARGO Therapeutics, Inc. (CRGX) And Encourages Investors to Reach Out

NEW YORK, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

10 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CARGO Therapeutics, Inc. (CRGX) And Encourages Stockholders to Reach Out

NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

12 days ago - Accesswire

CARGO Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CRGX

LOS ANGELES , Jan. 30, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ: CRGX) for...

13 days ago - PRNewsWire

Bronstein, Gewirtz & Grossman, LLC Is Investigating CARGO Therapeutics, Inc. (CRGX) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

13 days ago - Accesswire

The Schall Law Firm Urges Shareholders With Losses To Join An Investigation Into CARGO Therapeutics, Inc. For Securities Fraud

LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO The...

13 days ago - Accesswire

CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel) 1 ; Company believes results do not support a competitive benefit-risk profile for patients. CARGO ...

14 days ago - GlobeNewsWire

CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.

2 months ago - GlobeNewsWire

CARGO Therapeutics to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.

3 months ago - GlobeNewsWire

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma

3 months ago - GlobeNewsWire

CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) - - Completed $110 million private placement equity fina...

6 months ago - GlobeNewsWire

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

9 months ago - GlobeNewsWire

CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing

– Financing includes participation from new and existing investors –  – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND...

9 months ago - GlobeNewsWire

CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) (CRG-022); Currently on-track for interim results exp...

9 months ago - GlobeNewsWire

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors

– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) – – Appoin...

10 months ago - GlobeNewsWire